Corpus Intelligence IC Memo — PHOENIXVILLE HOSPITAL 2026-04-26 09:08 UTC
IC Memo — PHOENIXVILLE HOSPITAL
Investment Committee Memorandum | PA | 130 beds | Grade C | EBITDA uplift $12.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PHOENIXVILLE HOSPITAL

CCN 390127 | CHESTER, PA | 130 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PHOENIXVILLE HOSPITAL is a 130-bed suburban community hospital in CHESTER, PA with $169.3M in net patient revenue and a -15.3% operating margin. The hospital serves a payer mix of 27.8% Medicare, 1.9% Medicaid, and 70.3% commercial.

Thesis: Undervalued. Our ML models identify $12.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -15.3% to -7.9% (+736bps).

Net Revenue HCRIS$169.3M
Current EBITDA COMPUTED$-25.9M
Operating Margin COMPUTED-15.3%
Occupancy HCRIS65.0%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS17.5%
Distress Probability ML42.7%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
105
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -15.3% places it below the state median. Among 105 size-comparable peers (65-260 beds), the median margin is -6.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (65-260), prioritizing same-state peers. 105 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PHOENIXVILLE HOSPITAL (Target)PA130$169.3M-15.3%
WESTERN PENNSYLVANIA HOSPITALPA255$776.4M11.1%
ROBERT PACKER HOSPITALPA252$471.8M-2.1%
WILLIAMSPORT HOSPITAL & MEDICAPA227$459.8M-8.4%
MOUNT NITTANY MEDICAL CENTERPA248$441.7M12.6%
MEMORIAL MEDICAL CENTERPA241$435.1M-21.2%
THE CHAMBERSBURG HOSPITALPA234$435.1M5.2%
ST LUKE HOSPITAL ANDERSON CAMPPA193$433.0M20.6%
DUBOIS REGIONAL MEDICAL CENTERPA247$429.3M-15.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $12.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.6M+210bp18mo
Cost to Collect4.5%2.5%$3.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.1M+122bp9mo
Clean Claim Rate88.0%96.0%$108K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.6M
Cost to Collect
$3.4M
Denial Rate Reduction
$3.4M
A/R Days Reduction
$2.1M
Clean Claim Rate
$108K
Total EBITDA Uplift$12.5M
Current EBITDA$-25.9M
+ RCM Uplift+$12.5M
Pro Forma EBITDA$-13.5M
Current Margin-15.3%
Pro Forma Margin-7.9%
WC Released (1x)$6.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-39.9M$-46.4M0.00x-100.0%
Base (11x exit)10.0x11.0x$-39.9M$-63.9M0.00x-100.0%
Bull Case9.0x11.0x$-35.9M$-35.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-35.9M$-49.6M0.00x-100.0%
Bear Case11.0x10.0x$-43.9M$-95.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-43.9M$-119.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 105 hospitals with 65-260 beds
  • Same-state prioritization (n=106)
  • Comp margins: P25=-18.6% / P50=-6.5% / P75=5.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.